🌍 Exciting news from the European Commission! They have released the fourth implementing act titled “Health Technology Assessment – Joint Scientific Consultations on Medicinal Products for Human Use” for public consultation. This crucial document provides health technology developers with essential guidelines on how to seek early guidance on the evidence and data needed for conducting a joint clinical assessment (JCA) of their products. 𝐊𝐞𝐲 𝐚𝐬𝐩𝐞𝐜𝐭𝐬 𝐜𝐨𝐯𝐞𝐫𝐞𝐝 𝐢𝐧𝐜𝐥𝐮𝐝𝐞: ✴ Requesting Joint Scientific Consultations (JSCs) ✴ Parallel Consultation with the European Medicines Agency (EMA) ✴ Detailed deadlines and procedures ✴ Expert and stakeholder involvement ✴ Correspondence protocols ✴ Data protection and confidentiality measures This draft act is open for feedback until 29th October. Once finalised, it will take effect on 12 January 2025, streamlining the JSC framework under Regulation (EU) 2021/2282. 📅 𝐒𝐭𝐚𝐲 𝐭𝐮𝐧𝐞𝐝! Next week, Remap Consulting will provide an in-depth analysis of this act, highlighting its implications for health technology developers - https://lnkd.in/et8y4Z3S #MarketAccess #Pharma #HealthTech #EURegulations #ClinicalAssessment #Pharmaceuticals #JointScientificConsultations #EUHTA
Remap Consulting
Unternehmensberatung
Solving your pricing and market access challenges to improve patient access 🚀
Info
Remap Consulting specializes in pricing, reimbursement, and market access across the pharmaceutical, medical device and biotech sector. We take an evidence-based approach to 𝐨𝐩𝐭𝐢𝐦𝐢𝐳𝐞 𝐦𝐚𝐫𝐤𝐞𝐭 𝐚𝐜𝐜𝐞𝐬𝐬 by understanding your challenges and 𝐝𝐞𝐯𝐞𝐥𝐨𝐩𝐢𝐧𝐠 𝐜𝐮𝐬𝐭𝐨𝐦𝐢𝐳𝐞𝐝 𝐬𝐨𝐥𝐮𝐭𝐢𝐨𝐧𝐬 for your business needs. With our extensive background and wealth of experience within both consultancy and the pharmaceutical industry spanning a diverse array of therapy areas, along with first-hand experience of NICE practices, we bring expertise across the entire product lifecycle to the table. From early R&D development to patent expiry and beyond, we comprehend your perspective and provide tailored solutions. Our clients are usually individuals responsible for pricing and reimbursement who are asking: 💡 What is the best price for our product? 💡 Do we have sufficient evidence to support pricing and market access during launch? 💡 Are our in-house training capabilities adequate for securing pricing and reimbursement? 💡 What is the potential for pricing and market access in our business development opportunities? Want to learn more? Explore the articles and media on our website 🔗www.remapconsulting.com or reach out to us via email at 📧[email protected]. Ready for a discussion? We are always available for an introductory conversation to understand each other better - and together determine if further dialogue would be beneficial.
- Website
-
http://www.remapconsulting.com
Externer Link zu Remap Consulting
- Branche
- Unternehmensberatung
- Größe
- 11–50 Beschäftigte
- Hauptsitz
- Zug
- Art
- Privatunternehmen
- Gegründet
- 2014
- Spezialgebiete
- Pricing, Market Access, Reimbursement, Health Economics, Launch implementation, Training, eLearning, Real World Evidence, Drug Pricing, Health Technology Assessments, NICE submissions, Improve Patient Access, Pharmaceuticals, META Tool Facilitator, Launch strategy, Biosimilars, Managed entry agreements, Payer insights, Payer Value Proposition development und Orphan drugs
Orte
-
Primär
Industriestrasse 47
Zug, 6300, CH
-
Alderley Park
Macclesfield, England SK10 4, GB
Beschäftigte von Remap Consulting
-
Paul Craddy
Managing Director | Remap Consulting | Pricing & Reimbursement │ Market Access | Value & Evidence Strategy | Expert
-
Darja Debevec
Associate Director at Remap Consulting
-
Charles Hewitt
Director at Remap Consulting
-
Sarah Bailey
Versatile professional with cross-industry expertise driving growth and innovation through expert presentation design, engaging learning materials…
Updates
-
🗣️ 𝐇𝐚𝐯𝐞 𝐲𝐨𝐮 𝐡𝐞𝐚𝐫𝐝? Remap Consulting is hosting a panel discussion on the Access & Pricing track at this year's #WODC. Our expert panel will dive into how evidence-generation strategies can support patient access, influence decision-making, and address the needs of diverse stakeholders, including payers, healthcare providers, and patient organisations. We'll discuss the challenges and opportunities in generating robust evidence to demonstrate value, support HTA submissions, and navigate the complex landscape of rare disease treatments 🚀 💬 𝐇𝐚𝐯𝐞 𝐪𝐮𝐞𝐬𝐭𝐢𝐨𝐧𝐬 𝐨𝐫 𝐬𝐩𝐞𝐜𝐢𝐟𝐢𝐜 𝐭𝐨𝐩𝐢𝐜𝐬 𝐲𝐨𝐮 𝐰𝐚𝐧𝐭 𝐜𝐨𝐯𝐞𝐫𝐞𝐝? We want to hear from you! Please share your questions in advance to help us make this session as impactful and relevant as possible. 👉 Submit your questions now: https://lnkd.in/eZe34xUG #MarketAccess #RareDiseases #PatientEngagement #Pharma #Healthcare #OrphanDrugs World Orphan Drug Congress Europe
-
#Orphandrugs play a critical role in treating rare diseases, but their development often comes with high costs and a limited patient population. Despite their importance, the increasing number of these treatments impacts healthcare budgets, leading to rising costs for health systems. 🤔 This article explores key differences in how the US and Europe approach orphan drug accessibility. 𝐉𝐨𝐢𝐧 𝐭𝐡𝐞 𝐜𝐨𝐧𝐯𝐞𝐫𝐬𝐚𝐭𝐢𝐨𝐧 by sharing your insights in the comments 👇 #marketaccess #patientaccess #wodc #rarediseases #healthcare #pharmaceuticals #patientcare
-
🌟 Only 4 weeks until World Orphan Drug Congress Europe! 🔊 We're excited to introduce you to the pricing and market access experts from Remap Consulting attending this year's event: 👩💼 Mariam Bibi, Practice Lead - speaking on 24th Oct! 👩💼 Amy Boyers, Associate Director 👨💼 Amrit Kaliasethi, Senior Consultant 👩💼 Solen Monteil, Analyst 👩💼 Tia Kwong, Analyst 🔎 Our team will be focusing on key discussions around pricing strategies, reimbursement pathways, and patient access to ensure that innovative therapies can reach those who need them most. 𝐌𝐞𝐞𝐭 𝐮𝐬 𝐚𝐭 𝐛𝐨𝐨𝐭𝐡 𝟔𝟐 or book an informal chat 👉 [email protected]. We look forward to seeing you there! #WODC #MarketAccess #PatientAccess #RareDiseases #OrphanDrugs #RealWorldEvidence #HTA #EUHTA #Pharmaceuticals #Healthcare
-
In the world of #raredisease treatments, generating evidence is no easy feat. With small patient populations and limited comparators, traditional randomised controlled trials (RCTs) often fail to resolve uncertainties. This is where Real-World Evidence (RWE) comes into play—but does it always provide the answers? Discover how a robust RWE strategy can make the difference in securing #HTA approvals and ensuring #patientaccess ⚕ #RareDiseases #RealWorldEvidence #RWE #HealthcareStrategy #Pharma #OrphanDrugs #MarketAccess #Healthcare
Can Real-World Evidence overcome uncertainty in Rare disease treatments?
Remap Consulting auf LinkedIn
-
It’s always encouraging to receive thoughtful feedback from clients, especially when working on complex projects with tight turnarounds. 🤩 💬 "𝘛𝘩𝘦 𝘙𝘦𝘮𝘢𝘱 𝘵𝘦𝘢𝘮 𝘩𝘢𝘷𝘦 𝘣𝘦𝘦𝘯 𝘤𝘰𝘯𝘴𝘪𝘴𝘵𝘦𝘯𝘵𝘭𝘺 𝘴𝘶𝘱𝘱𝘰𝘳𝘵𝘪𝘷𝘦 𝘵𝘩𝘳𝘰𝘶𝘨𝘩𝘰𝘶𝘵 𝘦𝘷𝘦𝘳𝘺 𝘱𝘩𝘢𝘴𝘦 𝘰𝘧 𝘰𝘶𝘳 𝘱𝘳𝘰𝘫𝘦𝘤𝘵. 𝘛𝘩𝘦𝘪𝘳 𝘨𝘶𝘪𝘥𝘢𝘯𝘤𝘦 𝘩𝘢𝘴 𝘣𝘦𝘦𝘯 𝘪𝘯𝘴𝘵𝘳𝘶𝘮𝘦𝘯𝘵𝘢𝘭 𝘪𝘯 𝘩𝘦𝘭𝘱𝘪𝘯𝘨 𝘶𝘴 𝘮𝘢𝘬𝘦 𝘬𝘦𝘺 𝘥𝘦𝘤𝘪𝘴𝘪𝘰𝘯𝘴 𝘧𝘰𝘳 𝘌𝘈𝘔𝘚. 𝘞𝘩𝘦𝘯𝘦𝘷𝘦𝘳 𝘸𝘦’𝘷𝘦 𝘩𝘢𝘥 𝘲𝘶𝘦𝘴𝘵𝘪𝘰𝘯𝘴, 𝘵𝘩𝘦𝘺’𝘷𝘦 𝘣𝘦𝘦𝘯 𝘢𝘯𝘴𝘸𝘦𝘳𝘦𝘥 𝘱𝘳𝘰𝘮𝘱𝘵𝘭𝘺, 𝘢𝘯𝘥 𝘢𝘤𝘵𝘪𝘰𝘯𝘴 𝘢𝘳𝘦 𝘤𝘰𝘯𝘴𝘪𝘴𝘵𝘦𝘯𝘵𝘭𝘺 𝘧𝘰𝘭𝘭𝘰𝘸𝘦𝘥 𝘶𝘱 𝘸𝘪𝘵𝘩 𝘶𝘱𝘥𝘢𝘵𝘦𝘥 𝘵𝘪𝘮𝘦𝘭𝘪𝘯𝘦𝘴. 𝘛𝘩𝘦𝘪𝘳 𝘦𝘧𝘧𝘪𝘤𝘪𝘦𝘯𝘤𝘺 𝘩𝘢𝘴 𝘣𝘦𝘦𝘯 𝘢 𝘨𝘢𝘮𝘦-𝘤𝘩𝘢𝘯𝘨𝘦𝘳, 𝘦𝘴𝘱𝘦𝘤𝘪𝘢𝘭𝘭𝘺 𝘨𝘪𝘷𝘦𝘯 𝘵𝘩𝘦 𝘤𝘰𝘮𝘱𝘭𝘦𝘹𝘪𝘵𝘺 𝘰𝘧 𝘰𝘶𝘳 𝘱𝘳𝘦𝘱𝘢𝘳𝘢𝘵𝘪𝘰𝘯𝘴 𝘧𝘰𝘳 𝘕𝘐𝘊𝘌 𝘴𝘶𝘣𝘮𝘪𝘴𝘴𝘪𝘰𝘯. 𝘞𝘰𝘳𝘬𝘪𝘯𝘨 𝘸𝘪𝘵𝘩 𝘴𝘶𝘤𝘩 𝘢 𝘥𝘦𝘥𝘪𝘤𝘢𝘵𝘦𝘥 𝘢𝘯𝘥 𝘳𝘦𝘴𝘱𝘰𝘯𝘴𝘪𝘷𝘦 𝘵𝘦𝘢𝘮 𝘩𝘢𝘴 𝘮𝘢𝘥𝘦 𝘢𝘭𝘭 𝘵𝘩𝘦 𝘥𝘪𝘧𝘧𝘦𝘳𝘦𝘯𝘤𝘦. 𝘙𝘦𝘮𝘢𝘱 𝘢𝘳𝘦 𝘩𝘪𝘨𝘩𝘭𝘺 𝘬𝘯𝘰𝘸𝘭𝘦𝘥𝘨𝘦𝘢𝘣𝘭𝘦 𝘢𝘯𝘥 𝘳𝘦𝘴𝘱𝘰𝘯𝘴𝘪𝘷𝘦 – 𝘵𝘩𝘦𝘪𝘳 𝘦𝘹𝘱𝘦𝘳𝘪𝘦𝘯𝘤𝘦𝘥 𝘪𝘯𝘴𝘪𝘨𝘩𝘵𝘴 𝘩𝘦𝘭𝘱 𝘶𝘴 𝘥𝘦𝘧𝘪𝘯𝘦 𝘢𝘯𝘥 𝘢𝘭𝘪𝘨𝘯 𝘰𝘯 𝘰𝘶𝘳 𝘤𝘩𝘢𝘭𝘭𝘦𝘯𝘨𝘦𝘴 𝘦𝘷𝘦𝘳𝘺 𝘴𝘵𝘦𝘱 𝘰𝘧 𝘵𝘩𝘦 𝘸𝘢𝘺." We’re incredibly grateful to Hiba for sharing such great feedback on our recent project together. It’s always rewarding to know that our collaboration is making a real impact. 🎯 If you’re preparing for similar challenges, we’d be happy to explore how we can support you. Message us today at [email protected]. #Teamwork #Collaboration #Efficiency #NICEsubmission #EAMS #ClientSupport #MarketAccess #Pharma #Healthcare
-
🎉 Please join us in welcoming Mariam Bibi to the Remap Consulting team as Practice Lead! “Mariam's vast experience and passion for fostering a collaborative and inclusive environment will greatly enhance our team's capabilities and client offerings. We look forward to the valuable insights and leadership she will bring," said Paul, Managing Director. 👋 Feel free to connect and say hello at [email protected] and view her profile. #marketaccess #healthcare #pharmaceutical #consultancyservices #newcareer #newbeginnings #careerdevelopment #mentoring
-
Do you find the #HTA process for orphan drugs challenging? 🧬 From navigating limited clinical evidence to demonstrating cost-effectiveness, we explore strategic approaches and key considerations that can make a difference in securing HTA approval. If you're involved in rare disease drug development and looking to better understand how to achieve HTA success, this is a must-read! 💡 📅 We'll be attending the World Orphan Drug Congress in Barcelona this October and welcome the opportunity to discuss how Remap Consulting can support you in gaining HTA approval for your rare and orphan products. Connect with Kate Noble at [email protected] today. #OrphanDrugs #RareDiseases #HTAApproval #MarketAccess #WODC #RemapConsulting #Healthcare #PatientAccess
Strategic approaches to achieving HTA approval for orphan drugs
Remap Consulting auf LinkedIn
-
🌟 Big news at Remap Consulting! 🌟 We’re thrilled to welcome five fantastic new team members to our growing team! 🎉 👋 Say hello to Richard Sloggett, Amy Boyers, Amrit Kaliasethi, Ella Odams, and Kacper Swierk! Each brings fresh perspectives, valuable expertise, and a shared passion for driving positive change in the world of #marketaccess. As we mark a decade of growth, we're grateful for the unique skills and commitment each team member brings, helping us continue to provide the best support for our partners. Get to know more about them here 👉 https://lnkd.in/e5-THY9Y 🌱 𝐏𝐚𝐬𝐬𝐢𝐨𝐧𝐚𝐭𝐞 𝐚𝐛𝐨𝐮𝐭 𝐦𝐚𝐤𝐢𝐧𝐠 𝐚 𝐝𝐢𝐟𝐟𝐞𝐫𝐞𝐧𝐜𝐞? A problem-solver looking for a challenge? Love the #pharma industry? Send us a message to learn about exciting opportunities! #healthcare #teamwork #newbeginnings #careers #pharmalife #remapconsulting #welcometotheteam
-
Have you heard? 👂 The NICE - National Institute for Health and Care Excellence has reached an incredible milestone with its 1000th #technologyappraisal, approving Iptacopan for paroxysmal nocturnal haemoglobinuria (PNH). This landmark achievement reflects NICE's ongoing commitment to ensuring that patients in the UK have access to the most effective and value-driven treatments. Iptacopan's approval is a significant step forward in patient care, offering a more convenient, oral alternative to traditional intravenous therapies. This innovation not only addresses unmet needs in the treatment of PNH but also enhances patient quality of life. For pharmaceutical companies, this appraisal underscores the importance of developing treatments that deliver strong clinical outcomes while being cost-effective and patient-friendly. The emphasis on robust clinical and economic evidence by #NICE highlights the evolving landscape of healthcare, where balancing effectiveness, convenience, and cost is more crucial than ever. Looking for more insights? Take a look today ➡ https://lnkd.in/ee7u5_gQ #Healthcare #RareDiseases #PatientCare #Pharma #MarketAccess #PatientAccess #NHS #LifeSciences